vs
Side-by-side financial comparison of Amphastar Pharmaceuticals, Inc. (AMPH) and Limbach Holdings, Inc. (LMB). Click either name above to swap in a different company.
Amphastar Pharmaceuticals, Inc. is the larger business by last-quarter revenue ($183.1M vs $138.9M, roughly 1.3× Limbach Holdings, Inc.). Amphastar Pharmaceuticals, Inc. runs the higher net margin — 13.3% vs 3.2%, a 10.2% gap on every dollar of revenue. On growth, Limbach Holdings, Inc. posted the faster year-over-year revenue change (4.3% vs -1.8%). Over the past eight quarters, Limbach Holdings, Inc.'s revenue compounded faster (6.6% CAGR vs 3.2%).
Amphastar Pharmaceuticals is a publicly traded American speciality pharmaceutical company. It was incorporated in May 2004 and primarily develops, manufactures, and sells inhalation and intranasal products.
Limbach Flugmotoren is a Chinese-owned company based in Germany that produces aircraft engines.
AMPH vs LMB — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $183.1M | $138.9M |
| Net Profit | $24.4M | $4.4M |
| Gross Margin | 46.8% | 22.4% |
| Operating Margin | 19.4% | 0.8% |
| Net Margin | 13.3% | 3.2% |
| Revenue YoY | -1.8% | 4.3% |
| Net Profit YoY | -35.7% | — |
| EPS (diluted) | $0.51 | $0.36 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $138.9M | ||
| Q4 25 | $183.1M | $186.9M | ||
| Q3 25 | $191.8M | $184.6M | ||
| Q2 25 | $174.4M | $142.2M | ||
| Q1 25 | $170.5M | $133.1M | ||
| Q4 24 | $186.5M | $143.7M | ||
| Q3 24 | $191.2M | $133.9M | ||
| Q2 24 | $182.4M | $122.2M |
| Q1 26 | — | $4.4M | ||
| Q4 25 | $24.4M | $12.3M | ||
| Q3 25 | $17.4M | $8.8M | ||
| Q2 25 | $31.0M | $7.8M | ||
| Q1 25 | $25.3M | $10.2M | ||
| Q4 24 | $38.0M | $9.8M | ||
| Q3 24 | $40.4M | $7.5M | ||
| Q2 24 | $37.9M | $6.0M |
| Q1 26 | — | 22.4% | ||
| Q4 25 | 46.8% | 25.7% | ||
| Q3 25 | 51.4% | 24.2% | ||
| Q2 25 | 49.6% | 28.0% | ||
| Q1 25 | 50.0% | 27.6% | ||
| Q4 24 | 46.5% | 30.3% | ||
| Q3 24 | 53.3% | 27.0% | ||
| Q2 24 | 52.2% | 27.4% |
| Q1 26 | — | 0.8% | ||
| Q4 25 | 19.4% | 9.4% | ||
| Q3 25 | 13.2% | 7.2% | ||
| Q2 25 | 24.2% | 7.5% | ||
| Q1 25 | 21.9% | 5.9% | ||
| Q4 24 | 24.2% | 9.1% | ||
| Q3 24 | 29.8% | 8.1% | ||
| Q2 24 | 30.3% | 6.7% |
| Q1 26 | — | 3.2% | ||
| Q4 25 | 13.3% | 6.6% | ||
| Q3 25 | 9.0% | 4.8% | ||
| Q2 25 | 17.8% | 5.5% | ||
| Q1 25 | 14.8% | 7.7% | ||
| Q4 24 | 20.4% | 6.9% | ||
| Q3 24 | 21.1% | 5.6% | ||
| Q2 24 | 20.8% | 4.9% |
| Q1 26 | — | $0.36 | ||
| Q4 25 | $0.51 | $1.01 | ||
| Q3 25 | $0.37 | $0.73 | ||
| Q2 25 | $0.64 | $0.64 | ||
| Q1 25 | $0.51 | $0.85 | ||
| Q4 24 | $0.74 | $0.81 | ||
| Q3 24 | $0.78 | $0.62 | ||
| Q2 24 | $0.73 | $0.50 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $282.8M | $15.8M |
| Total DebtLower is stronger | $608.7M | $56.6M |
| Stockholders' EquityBook value | $788.8M | $196.3M |
| Total Assets | $1.6B | $377.0M |
| Debt / EquityLower = less leverage | 0.77× | 0.29× |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $15.8M | ||
| Q4 25 | $282.8M | $11.3M | ||
| Q3 25 | $276.2M | $9.8M | ||
| Q2 25 | $231.8M | $38.9M | ||
| Q1 25 | $236.9M | $38.1M | ||
| Q4 24 | $221.6M | $44.9M | ||
| Q3 24 | $250.5M | $51.2M | ||
| Q2 24 | $217.8M | $59.5M |
| Q1 26 | — | $56.6M | ||
| Q4 25 | $608.7M | $30.5M | ||
| Q3 25 | $608.6M | $56.3M | ||
| Q2 25 | $607.7M | $28.4M | ||
| Q1 25 | $603.9M | $23.7M | ||
| Q4 24 | $601.6M | $23.6M | ||
| Q3 24 | $596.4M | $20.5M | ||
| Q2 24 | $586.9M | $19.7M |
| Q1 26 | — | $196.3M | ||
| Q4 25 | $788.8M | $195.7M | ||
| Q3 25 | $776.7M | $181.6M | ||
| Q2 25 | $757.5M | $170.5M | ||
| Q1 25 | $751.3M | $161.1M | ||
| Q4 24 | $732.3M | $153.5M | ||
| Q3 24 | $727.7M | $142.2M | ||
| Q2 24 | $713.3M | $133.0M |
| Q1 26 | — | $377.0M | ||
| Q4 25 | $1.6B | $381.1M | ||
| Q3 25 | $1.7B | $409.1M | ||
| Q2 25 | $1.6B | $343.0M | ||
| Q1 25 | $1.6B | $336.4M | ||
| Q4 24 | $1.6B | $352.1M | ||
| Q3 24 | $1.5B | $324.4M | ||
| Q2 24 | $1.5B | $303.9M |
| Q1 26 | — | 0.29× | ||
| Q4 25 | 0.77× | 0.16× | ||
| Q3 25 | 0.78× | 0.31× | ||
| Q2 25 | 0.80× | 0.17× | ||
| Q1 25 | 0.80× | 0.15× | ||
| Q4 24 | 0.82× | 0.15× | ||
| Q3 24 | 0.82× | 0.14× | ||
| Q2 24 | 0.82× | 0.15× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $32.9M | — |
| Free Cash FlowOCF − Capex | $24.6M | — |
| FCF MarginFCF / Revenue | 13.4% | — |
| Capex IntensityCapex / Revenue | 4.5% | — |
| Cash ConversionOCF / Net Profit | 1.35× | — |
| TTM Free Cash FlowTrailing 4 quarters | $121.2M | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $32.9M | $28.1M | ||
| Q3 25 | $52.6M | $13.3M | ||
| Q2 25 | $35.6M | $2.0M | ||
| Q1 25 | $35.1M | $2.2M | ||
| Q4 24 | $29.0M | $19.3M | ||
| Q3 24 | $60.0M | $4.9M | ||
| Q2 24 | $69.1M | $16.5M |
| Q1 26 | — | — | ||
| Q4 25 | $24.6M | $27.9M | ||
| Q3 25 | $47.2M | $12.8M | ||
| Q2 25 | $25.0M | $1.2M | ||
| Q1 25 | $24.4M | $11.0K | ||
| Q4 24 | $16.6M | $18.0M | ||
| Q3 24 | $46.2M | $4.6M | ||
| Q2 24 | $63.1M | $13.2M |
| Q1 26 | — | — | ||
| Q4 25 | 13.4% | 14.9% | ||
| Q3 25 | 24.6% | 7.0% | ||
| Q2 25 | 14.3% | 0.8% | ||
| Q1 25 | 14.3% | 0.0% | ||
| Q4 24 | 8.9% | 12.5% | ||
| Q3 24 | 24.1% | 3.4% | ||
| Q2 24 | 34.6% | 10.8% |
| Q1 26 | — | — | ||
| Q4 25 | 4.5% | 0.1% | ||
| Q3 25 | 2.8% | 0.3% | ||
| Q2 25 | 6.1% | 0.6% | ||
| Q1 25 | 6.3% | 1.7% | ||
| Q4 24 | 6.7% | 0.9% | ||
| Q3 24 | 7.2% | 0.3% | ||
| Q2 24 | 3.3% | 2.7% |
| Q1 26 | — | — | ||
| Q4 25 | 1.35× | 2.29× | ||
| Q3 25 | 3.03× | 1.52× | ||
| Q2 25 | 1.15× | 0.26× | ||
| Q1 25 | 1.39× | 0.22× | ||
| Q4 24 | 0.76× | 1.96× | ||
| Q3 24 | 1.48× | 0.66× | ||
| Q2 24 | 1.82× | 2.77× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
AMPH
| Other Products | $62.4M | 34% |
| Baqsimi | $46.7M | 26% |
| Primatenemist | $27.9M | 15% |
| Epinephrine | $17.1M | 9% |
| Lidocaine | $14.9M | 8% |
| Glucagon | $14.1M | 8% |
LMB
| ODR | $99.8M | 72% |
| GCR | $39.0M | 28% |
